Loss of partner, funding no deterrent to Replidyne

LOUISVILLE – When the FDA pulled the rug out from under the feet of Replidyne Inc. last October, the principals didn’t let it get them down.

When the company’s partner and primary funder, Forest Laboratories Inc., ended a yearlong collaboration in February, Replidyne’s executives brushed off the dust and got back on the horse.

That’s just the way it goes in the biopharmaceutical business, said Replidyne President and Chief Executive Ken Collins and Chief Scientific Officer Nebojsa Janjic. There’s always regulatory risk.

In the case of Replidyne’s faropenem medoxomil, an oral antibiotic for the treatment of certain upper respiratory infections, the problem…